Developing novel therapeutics with a deep focus on modifying aging.
With a focus on prevention, we're developing a range of clinically validated therapeutic products that modify the way we age.
Robust investor returns facilitiated by a unique and integrated pipeline.
Currently developing ten leading programs with a clearly defined route to market.
With a focus on prevention, we are developing a range of therapeutic interventions that modify the way we age.
Robust investor returns facilitated by a unique and integrated pipeline.
Currently developing ten leading programs with a clearly defined route to market.
Using an integrated model, we cover the entire aging market with a variety of advanced therapeutic interventions that target the biology of aging to treat multiple indications.
New CEO set to Marshall longevity with a pipeline that delivers immediate therapeutic benefit, but always has an eye on a future preventative angle. Back in January, we reported that...
Biotech company Morphoceuticals has announced it closed an $8 million Seed-2 funding round led by Prime Movers Lab and initial investor Juvenescence. Seed funding will advance programs using electroceuticals in limb regeneration and...
Juvenescence sponsored this article in Health, which discusses how your body can benefit from an efficient metabolism.
